Scope of the Report The report entitled “Global Biologics Outsourcing Services Market: Size, Trends & Forecasts (2017-2021)”, provides analysis of the global biologics outsourcing services market, with detailed analysis of market size and growth, and segmentation of the industry. The analysis includes the market by value, by R&D spending and by segmentation. Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global biologics outsourcing services market has also been forecasted for the years 2017-2021, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. Wuxi Biologics, Lonza, Patheon and Boehringer Ingelheim are some of the key players operating in the global biologics outsourcing services market, whose company profiling has been done in the report. In this segment of the report, business overview, financial overview and business strategies of the companies are provided. Company Coverage Wuxi Biologics Lonza Patheon Boehringer Ingelheim Executive Summary Pharma industry complies with the development and production of varied types... Research Beam Model: Research Beam Product ID: 2028347 850 USD New
Global Biologics Outsourcing Services Market: Size, Trends & Forecasts (2017-2021)
 
 

Global Biologics Outsourcing Services Market: Size, Trends & Forecasts (2017-2021)

  • Category : Diagnostic and Biotech
  • Published On : August   2017
  • Pages : 72
  • Publisher : Daedal Research
 
 
 
Scope of the Report

The report entitled “Global Biologics Outsourcing Services Market: Size, Trends & Forecasts (2017-2021)”, provides analysis of the global biologics outsourcing services market, with detailed analysis of market size and growth, and segmentation of the industry. The analysis includes the market by value, by R&D spending and by segmentation.

Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global biologics outsourcing services market has also been forecasted for the years 2017-2021, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Wuxi Biologics, Lonza, Patheon and Boehringer Ingelheim are some of the key players operating in the global biologics outsourcing services market, whose company profiling has been done in the report. In this segment of the report, business overview, financial overview and business strategies of the companies are provided.

Company Coverage

Wuxi Biologics
Lonza
Patheon
Boehringer Ingelheim

Executive Summary

Pharma industry complies with the development and production of varied types of drugs and medicines for diagnosis, cure, treatment or prevention of disease. Pharmaceutical drugs are classified on many basis such as analgesics, antimalarial, antibiotics, mood stabilizers, hormone replacements, stimulants, tranquilizers, etc.

Usually all the pharmaceutical medicines can be segmented biologics and non-biologics. Biologics are those medicines which are manufactured with a living cell such as microorganism and composed of complex combination of substances like sugar, proteins, etc. Biologics are mainly used in the treatment of number of chronic diseases (cancer, diabetes, blood pressure, etc.). Biologics are of many types based on their source of development: blood component, blood, tissues, cells, vaccines, allergens. Biologics also consist of of many side effects.

Biologics outsourcing is defined as outsourcing of various biologics services. Four steps in biologics outsourcing value chain are: discovery, preclinical development, clinical development and commercialization. Biologics service outsourcing provides many advantages such as flexible and convenient method for research and development of drugs, reduction in capital investment, etc. The global biologics outsourcing services market is expected to increase at high growth rates during the forecasted period (2017-2021).

The global biologics outsourcing services market is supported by various growth drivers, such as growing demand for outsourcing variety, demand of antibody conjugate, increasing biologics approvals, etc. Yet, the market faces certain challenges, such as, lack of knowledge in biopharma industry, complexities in handling biologics, etc. Few new market trends are also provided such as, outsourcing of clinical trials, demand for contract research organization and contract manufacturing organization, growing bio-analytical testing demand, etc.
1. Executive Summary

2. Introduction

2.1 Pharmaceutical Drug: An Overview

2.1.1 Pharmaceutical Drugs Meaning
2.1.2 Classification of Pharmaceutical Drugs
2.1.3 Types of Pharmaceutical Medicines
2.1.4 Segments of Pharmaceutical Medicines

2.2 Biologics : An Overview

2.2.1 Biologics Definition
2.2.2 Biologics Medical Uses
2.2.3 Types of Biologics Products
2.2.4 Side Effects of Biologics
2.2.5 Biologics Outsourcing
2.2.6 Biologics Outsourcing Value Chain
2.2.7 Advantages of Biologics Outsourcing

3. Global Market Analysis

3.1 Global Pharmaceutical Market: An Analysis

3.1.1 Global Pharmaceutical Market by Value
3.1.2 Global Pharmaceutical Market by Segment
3.1.3 Global Non-Biologics Market by Value

3.2 Global Biologics Market: An Analysis

3.2.1 Global Biologics Market by Value
3.2.2 R&D Spending on Biologics Market by Value
3.2.3 Global Biologics Outsourcing Services Market by Value
3.2.4 Global Biologics Outsourcing Services by Penetration

4. Market Dynamics

4.1 Growth Drivers

4.1.1 Increasing Research and Development Funding
4.1.2 Growing Demand for Outsourcing Variety
4.1.3 Innovative Treatment for Previously Untreatable Diseases
4.1.4 Demand of Antibody Conjugate
4.1.5 Bounce in Company Collaboration
4.1.6 Increasing Biologics Approvals
4.1.7 Raising Autoimmune Disease Prevalence
4.1.8 Favorable States in China
4.1.9 Flexible and Customizable CMO Market
4.1.10 Increasing Household Disposable Income
4.1.11 Emergence and Approval of Affordable Biosimilars

4.2 Challenges

4.2.1 Lack of Knowledge in Biopharma Industry
4.2.2 Time Consuming and Capital Intensive Investment
4.2.3 Complexities in Handling Biologics
4.2.4 Costly Drug Development Process
4.2.5 Conflict of Interest Between Companies

4.3 Market Trends

4.3.1 Suppliers With Technical Competence
4.3.2 Outsourcing of Clinical Trials
4.3.3 Growing Bio-analytical Testing Demand
4.3.4 Demand for Contract Research Organization and Contract Manufacturing Organization

5. Competitive Landscape

5.1 Biologics Service Outsourcing Market by Players

5.1.1 Biologics Outsourcing Services Market Share by Player
5.1.2 Biologics Service Outsourcing Market Players by Service Spectrum

6. Company Profiling

6.1 Wuxi Biologics
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategy

6.2 Lonza
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategy

6.3 Boehringer Ingelheim
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategy

6.4 Patheon Inc.
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategy

List of Figures

Figure 1: Classification of Pharmaceutical Drugs
Figure 2: Types of Pharmaceutical Drugs
Figure 3: Segments of Pharmaceutical Medicines
Figure 4: Types of Biologics Products
Figure 5: Side Effects of Biologics
Figure 6: Biologics Outsourcing Value Chain
Figure 7: Advantages of Biologics Outsourcing
Figure 8: Global Pharmaceutical Market by Value; 2011-2016 (US$ Billion)
Figure 9: Global Pharmaceutical Market by Value; 2017-2021 (US$ Billion)
Figure 10: Global Pharmaceutical Market by Segment; 2016 (Percentage, %)
Figure 11: Global Non-Biologics Market by Value; 2011-2016 (US$ Billion)
Figure 12: Global Non-Biologics Market by Value; 2017-2021 (US$ Billion)
Figure 13: Global Biologics Market by Value; 2011-2016 (US$ Billion)
Figure 14: Global Biologics Market by Value; 2017-2021 (US$ Billion)
Figure 15: R&D Spending on Biologics Market by Value; 2015-2021 (US$ Billion)
Figure 16: Global Biologics Outsourcing Services Market by Value; 2011-2016 (US$ Billion)
Figure 17: Global Biologics Outsourcing Services Market by Value; 2017-2021 (US$ Billion)
Figure 18: Global Biologics Outsourcing Services by Penetration; 2016 (Percentage, %)
Figure 19: FDA Approved Medicines; 2010-2015
Figure 20: Prevalence of Diagnosed Autoimmune Conditions; 2016
Figure 21: The Global GNI Per Capita; 2011-2015 (US$)
Figure 22: Biologics Outsourcing Services Market Share by Player; 2015 (Percentage, %)
Figure 23: Wuxi Biologics Revenue; 2014-2016 (US$ Million)
Figure 24: Wuxi Biologics Revenue by Region; 2016 (Percentage, %)
Figure 25: Lonza Sales; 2012-2016 (US$ Billion)
Figure 26: Lonza Sales by Segment; 2016 (Percentage, %)
Figure 27: Lonza Sales by Region; 2016 (Percentage, %)
Figure 28: Boehringer Ingelheim Net Sales; 2013-2016 (US$ Billion)
Figure 29: Boehringer Ingelheim Net Sales by Segment; 2016 (Percentage, %)
Figure 30: Boehringer Ingelheim Net Sales by Region ; 2016 (Percentage, %)
Figure 31: Patheon Revenue; 2012-2016 (US$ Million)
Figure 32: Patheon Revenue by Segments; 2016 (Percentage, %)
Table 1: Top Collaborations in Pharmaceutical Companies; 2015-2016
Table 2: New Approved Biosimilars; 2015-2017
Table 3: Biologics Service Outsourcing Market Players by Service Spectrum; 2017
PURCHASE OPTIONS
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter

 
 
REQUEST SAMPLE    ASK FOR DISCOUNT